Henry Zubaida

Henry Zubaida is an Investment Director on Gilde Healthcare's Venture & Growth team, which he joined in 2018 as an Investment Manager. Gilde Healthcare is a specialized healthcare investor headquartered in Utrecht, the Netherlands, with more than €800 million ($900 million) under management across its Venture & Growth, Private Equity, and Climate Solutions strategies. Within the firm, Zubaida focuses primarily on medical devices and therapeutics.

Before joining Gilde, Zubaida worked in business development at Biolinq, a US-based startup developing a next-generation continuous glucose monitoring platform. Earlier, he gained venture deal-sourcing and evaluation experience at M Ventures (the corporate venture arm of Merck KGaA) in the Netherlands, and worked within Merck KGaA itself. He began his career as a management consultant in London.

Zubaida holds a Master's degree in Bioscience Enterprise from the University of Cambridge, a program that bridges life-science research with commercialization and entrepreneurship — a fitting foundation for a healthtech investor who evaluates both the clinical and commercial merits of medtech and therapeutics companies.

Note: aggregated stub records that describe him as an "Associate" / "Angel Investor" focused on "Seed Round" deals are inaccurate. His verified role is Investment Director at Gilde Healthcare, an institutional venture & growth capital firm that writes eight-figure checks.

• Invests through Gilde Healthcare Venture & Growth, backing disruptive companies in medtech, digital health, medical instruments, diagnostics, and therapeutics across Europe and North America.
• Typical equity investments of roughly €10–40 million per portfolio company, frequently leading or co-leading rounds and taking a board seat or board-observer role.
• Personal focus areas within the firm are medical devices and therapeutics, informed by his operating background in continuous glucose monitoring (Biolinq) and corporate venture (M Ventures).
• Gilde looks to lead new investments in digital health, diagnostics, medical devices, therapeutics, and healthcare services — favoring companies with strong clinical evidence and a clear path to regulatory approval and commercialization.